Education
About Us
Working with TipRanks
Follow Us
Inogen (INGN)
NASDAQ:INGN
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.24Same Quarter Last Year
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: -19.80%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment. Inogen demonstrated strong revenue growth and improvements in the B2B channel and adjusted EBITDA. The collaboration with UL Medical and reduced operating expenses further contributed positively. However, significant declines in direct-to-consumer sales and rental revenue, coupled with a net loss, indicate challenges that need addressing. Despite positive trends, the balance between highlights and lowlights suggests a cautious outlook.Company Guidance
In the Inogen First Quarter 2025 Earnings Conference Call, the company provided guidance for the year, emphasizing expectations for revenue growth and profitability. Inogen anticipates reported revenue for the full year 2025 to be between $352 million and $355 million, reflecting a 5% to 6% increase from 2024. The revenue outlook for the second quarter is projected to be between $89 million and $91 million, marking flat to 3% growth compared to the same period in 2024. The company also expects to approach adjusted EBITDA breakeven for the full year 2025, demonstrating a focus on operational efficiencies and strategic investments. The guidance reflects Inogen's confidence in its strategic priorities, including driving top-line growth, advancing its path to sustained profitability, and expanding its innovation pipeline.Revenue Growth
Inogen delivered over $82 million in revenue for Q1 2025, reflecting a 5.5% year-over-year growth.
B2B Channel Performance
Domestic business-to-business revenue increased 29.9% to $21.5 million, and international business-to-business revenue increased 22.9% to $32 million.
Adjusted EBITDA Profitability
Positive adjusted EBITDA of $36,000 in Q1 2025 compared to a negative $7.6 million in the prior period.
UL Medical Collaboration
Finalized collaboration with UL Medical to distribute Inogen products in China and the US, with UL investing $27 million for a 9.9% stake in Inogen.
Improved Operating Expenses
Total operating expense decreased by 13.1% to $44 million in Q1 2025 compared to the prior period.
Balance Sheet Strength
Cash, cash equivalents, and restricted cash of $122.5 million with no debt outstanding.
---
INGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
INGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $7.17 | $6.35 | -11.44% |
Feb 25, 2025 | $9.52 | $8.11 | -14.81% |
Nov 07, 2024 | $9.46 | $11.09 | +17.23% |
Aug 06, 2024 | $8.15 | $11.08 | +35.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Inogen (INGN) report earnings?
Inogen (INGN) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Inogen (INGN) earnings time?
Inogen (INGN) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INGN EPS forecast?
INGN EPS forecast for the fiscal quarter 2025 (Q2) is -0.29.
---